Medicines & supplements – Current GIS Alerts 2026
Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
LECALPIN
It was found that in the outer cartons intended for the medicinal product Lecalpin 20 mg there were primary packages (blisters) of the medicinal product Lecalpin 10 mg, batch No. 268018. Potential effects: lack of treatment efficacy or improper dosing.
MILVANE
Lack of information on contraindications for the use of the medicinal product Milvane in combination with certain medicines used in antiviral therapy. Potential effects: lack of efficacy, adverse reactions, treatment complications.
SPASMOLINA
Incorrect expiry date was printed on outer packaging and required safety features (unique identifier and anti-tampering device) were missing, combined with lack of batch certification and release by the Qualified Person. Potential effects: lack of treatment efficacy, use of the product after expiry date, risk of falsification or tampering, treatment complications.
KALIUM EFFERVRSCENS BEZCUKROWY
Repeated complaints were reported regarding incorrectly printed expiry dates and it was found that the products lacked a unique identifier and tamper-evident safety feature on the packaging, as well as batch certification and release by the Qualified Person. Potential effects: lack of treatment efficacy, use after expiry, falsification risk, treatment complications.
FOLACID
Incorrect expiry date was printed, the prescription products lacked a unique identifier and tamper-evident safety feature on the packaging, and batches were not certified or released by a Qualified Person. Potential effects: lack of efficacy, use after expiry date, risk of falsification, therapy complications.
TRAMADOL SYNTEZA
Incorrect labelling of the expiry date on the outer packaging could mislead regarding the actual shelf life of the product, and the lack of recertification after repackaging means the product reached the market without full quality verification. Potential effects: lack of treatment efficacy or increased risk of adverse reactions when using the product after the true expiry date.
FOLACID
Incorrect expiry date marking on the packaging and lack of batch recertification after repackaging may lead to use of the product beyond the correct expiry date or of a product improperly released to the market. Potential effects: lack of efficacy or increased adverse effects.
SPASMOLINA
Incorrect expiry date marking was detected (“09.2019” instead of “10.2019”) and the product was reintroduced to the market after repackaging without the required certification and batch release by the Qualified Person. Potential effects: lack of treatment effectiveness or risk of using the product after its actual expiry date.
ANDEPIN
An incorrect print shortening the product expiry date by one month and reintroduction of the repackaged batch to the market without required certification and release by the Qualified Person may lead to use of the product after its actual expiry or with unverified quality. Potential effects: lack of efficacy or complications related to using the product after its expiry date.
KALIUM EFFERVRSCENS BEZCUKROWY
Incorrect expiry date was printed on the packaging and the packs lacked a unique identifier and tamper-evident safety feature, as well as batch certification by the Qualified Person. Potential effects: lack of treatment efficacy or use of the product after expiry, possible complications.
TRAMADOL SYNTEZA
Incorrect expiry date labelling on the packaging and lack of re-certification of the batch after repackaging may lead to use of the product after its true expiry date or use of a batch that was not properly released to the market. Potential effects: lack of efficacy or adverse effects related to using an expired medicine.
SPASMOLINA
Failure to include a unique identifier and tamper-evident feature on the packaging and placing the batch on the market without recertification and release by the Qualified Person may result in distribution of a product with unverified quality and authenticity. Potential effects: lack of efficacy or complications due to use of a product with unconfirmed quality.
ANDEPIN
Lack of a unique identifier and tamper‑evident feature, together with incorrect expiry date labelling, may prevent proper medicine identification and facilitate circulation of unauthorised or expired packs. Potential effects: lack of treatment efficacy or complications related to use of expired or falsified medicine.
VITAMINUM A + E SYNTEZA
The absence of a unique identifier and tamper‑evident device, together with placing batches on the market without proper certification and release by the Qualified Person, may result in incorrect identification, risk of falsification, or lack of confirmed quality and safety of therapy. Potential effects: lack of efficacy, treatment complications.
ENEMA
Identified risk of a decrease in the content of the preservative – methyl parahydroxybenzoate, meaning the product may not meet established quality requirements and may not ensure adequate microbiological stability. Potential effects: lack of efficacy, infections, complications in patients.
NuTRiflex Lipid special
It was found that the glucose solution may not meet specification requirements at the end of shelf-life, indicating a quality defect of the medicinal product and a potential threat to patients’ health or life. Potential effects: lack of treatment efficacy, metabolic disturbances, complications after infusion.
XALOPTIC FREE
It was found that the specification limit for related substances was exceeded in batches of the medicinal product Xaloptic Free, with a likelihood of this non‑compliance occurring in further batches. Potential effects: possible lack of efficacy or unforeseen adverse reactions.
XALOPTIC FREE
Exceeding specification limits for related substances content in several batches of Xaloptic Free and suspected occurrence of the same quality defect in further batches, indicating non‑compliance with quality requirements. Potential effects: lack of treatment efficacy, adverse reactions, therapy complications.
IRCOLON FORTE
Only a labelling error of the expiry date was found (02.2021 instead of 02.2020), with no indication of quality or safety hazards for the product. After confirmation of shelf-life extension to 3 years, the risk was considered negligible. Potential effects: none or minimal risk, possibly uncertainty about the actual expiry date.
ROTARIX
Irregularities in the manufacturing process were detected, leading to possible insufficient filling of the last 50 oral applicators of the Rotarix batch, meaning failure to meet quality requirements for the volume parameter. Potential effects: lack of vaccination efficacy.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.